Alnylam Pharmaceuticals Inc (ALNY)
146.07
+1.06
(+0.73%)
USD |
NASDAQ |
Apr 19, 10:58
Alnylam Pharmaceuticals Research and Development Expense (Quarterly): 272.14M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 272.14M |
| September 30, 2023 | 253.18M |
| June 30, 2023 | 248.53M |
| March 31, 2023 | 230.57M |
| December 31, 2022 | 262.04M |
| September 30, 2022 | 245.37M |
| June 30, 2022 | 205.71M |
| March 31, 2022 | 169.89M |
| December 31, 2021 | 229.05M |
| September 30, 2021 | 194.57M |
| June 30, 2021 | 182.64M |
| March 31, 2021 | 185.90M |
| December 31, 2020 | 168.47M |
| September 30, 2020 | 161.78M |
| June 30, 2020 | 155.00M |
| March 31, 2020 | 169.57M |
| December 31, 2019 | 201.30M |
| September 30, 2019 | 160.80M |
| June 30, 2019 | 163.89M |
| March 31, 2019 | 129.13M |
| December 31, 2018 | 131.04M |
| September 30, 2018 | 139.94M |
| June 30, 2018 | 137.58M |
| March 31, 2018 | 96.86M |
| December 31, 2017 | 117.77M |
| Date | Value |
|---|---|
| September 30, 2017 | 95.25M |
| June 30, 2017 | 90.63M |
| March 31, 2017 | 86.98M |
| December 31, 2016 | 105.01M |
| September 30, 2016 | 97.94M |
| June 30, 2016 | 83.17M |
| March 31, 2016 | 96.27M |
| December 31, 2015 | 82.84M |
| September 30, 2015 | 68.62M |
| June 30, 2015 | 67.01M |
| March 31, 2015 | 58.04M |
| December 31, 2014 | 55.55M |
| September 30, 2014 | 46.27M |
| June 30, 2014 | 44.67M |
| March 31, 2014 | 43.76M |
| December 31, 2013 | 32.11M |
| September 30, 2013 | 34.46M |
| June 30, 2013 | 24.22M |
| March 31, 2013 | 22.18M |
| December 31, 2012 | 21.68M |
| September 30, 2012 | 22.09M |
| June 30, 2012 | 21.72M |
| March 31, 2012 | 21.07M |
| December 31, 2011 | 23.37M |
| September 30, 2011 | 24.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
155.00M
Minimum
Jun 2020
272.14M
Maximum
Dec 2023
203.18M
Average
194.57M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 256.56M |
| Pfizer Inc | 2.815B |
| Blueprint Medicines Corp | 97.54M |
| Madrigal Pharmaceuticals Inc | 70.64M |
| Sarepta Therapeutics Inc | 195.52M |